Abstract: A hydroxyl generator unit includes an ultraviolet light source, a reaction chamber within interior space of the hydroxyl generator unit, environmental sensors and a smart optic controller coupled to environmental sensors and to the ultraviolet light source. The smart optic controller integrates environmental conditions, and in response to at least the environmental conditions, the smart optic controller generates an output signal to the ultraviolet light source to control to the hydroxyls generated by the hydroxyl generator unit. The smart optic controller includes at least one of an air flow sensor, a temperature sensor, a humidity sensor and a light sensor, to control operation of the hydroxyl generator unit. The smart optic controller includes a microcontroller that interrogates the sensors and that interfaces to external systems. The smart optic controller includes a near field communications circuit attached to a sensor communications link, and a control interface via an RS-485 connection.

Abstract: A hydroxyl generator unit includes an ultraviolet light source, a reaction chamber within interior space of the hydroxyl generator unit, environmental sensors and a smart optic controller coupled to environmental sensors and to the ultraviolet light source. The smart optic controller integrates environmental conditions, and in response to at least the environmental conditions, the smart optic controller generates an output signal to the ultraviolet light source to control to the hydroxyls generated by the hydroxyl generator unit. The smart optic controller includes at least one of an air flow sensor, a temperature sensor, a humidity sensor and a light sensor, to control operation of the hydroxyl generator unit. The smart optic controller includes a microcontroller that interrogates the sensors and that interfaces to external systems. The smart optic controller includes a near field communications circuit attached to a sensor communications link, and a control interface via an RS-485 connection.

Abstract: A hydroxyl generator unit includes an ultraviolet light source, a reaction chamber within interior space of the hydroxyl generator unit, environmental sensors and a smart optic controller coupled to environmental sensors and to the ultraviolet light source. The smart optic controller integrates environmental conditions, and in response to at least the environmental conditions, the smart optic controller generates an output signal to the ultraviolet light source to control to the hydroxyls generated by the hydroxyl generator unit. The smart optic controller includes at least one of an air flow sensor, a temperature sensor, a humidity sensor and a light sensor, to control operation of the hydroxyl generator unit. The smart optic controller includes a microcontroller that interrogates the sensors and that interfaces to external systems. The smart optic controller includes a near field communications circuit attached to a sensor communications link, and a control interface via an RS-485 connection.

Abstract: The disclosed apparatus may include a mounting structure. A first arm may be secured to the mounting structure and may extend from the mounting structure. A load cell may be mechanically coupled to the first arm to detect a first load applied to the first arm by relative movement between the first load cell and a viscous material in which the first arm may be submerged or at least partially disposed. A second arm may be secured to the mounting structure and may extend from the mounting structure. A second load cell may be mechanically coupled to the second arm to detect a second load applied to the second arm by relative movement between the second load cell and the viscous material. In one embodiment, load data related to the first and second loads may be used to estimate or determine at least one characteristic of the viscous material.

Abstract: The disclosed apparatus may include a mounting structure. A first arm may be secured to the mounting structure and extend from the mounting structure. A load cell may be mechanically coupled to the first arm to detect a first load applied to the first arm by relative movement between the first load cell and a viscous material in which the first arm may be submerged or at least partially disposed. A second arm may be secured to the mounting structure and extend from the mounting structure. A second load cell may be mechanically coupled to the second arm to detect a second load applied to the second arm by relative movement between the second load cell and the viscous material. In one embodiment, load data related to the first and second loads may be used to estimate or determine at least one characteristic of the viscous material.

Abstract: A pharmaceutical combination comprising an accelerated lymphocyte homing agent in free form or in pharmaceutically acceptable salt form, and one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor is used to treat or prevent insulin-producing cell graft rejection.

Abstract: A feed structure may be used in conjunction with a sedimentation vessel in order to separate solids and liquids, which may be in a slurry, from each other. The feed structure comprises a feed chamber housing a central wall. At least one port is positioned at the base of the chamber. A feedwell that is substantially concentric with the feed chamber is also used. The feed chamber is in communication with the feedwell, wherein slurry flows through the said port to access the feedwell. An outlet is positioned on the feedwell (such as near the bottom of the feedwell). Slurry may flow through the outlet into the sedimentation vessel.

Abstract: A feed system is used in a sedimentation vessel. The feed system includes an inlet for receiving a quantity of feed slurry and an outlet for delivering the feed slurry to a separation zone within the sedimentation vessel. The feed slurry includes a mixture of solids and liquids that are to be separated in a separation zone within the sedimentation vessel. An airlift pump is used to cycle at least a portion of either the separated solids or the separated liquids from the separation zone and return it to the feed system. This returned portion mixes with the feed slurry and may operate to dilute the feed slurry to a concentration for optimal separation. Additionally, feed conditioning chemicals may be mixed into the feed slurry prior to or after the mixing of the feed slurry with the returned portion of the separated products.

Abstract: A pharmaceutical combination comprising an accelerated lymphocyte homing agent in free form or in pharmaceutically acceptable salt form, and one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor is used to treat or prevent insulin-producing cell graft rejection.

Abstract: The invention provides a pharmaceutical combination comprising: a) at least one S1P receptor agonist, and b) at least one JAK3 kinase inhibitor and a method for treating or preventing autoimmune diseases or cell, tissue or organ graft rejection using such a combination.

Abstract: A feed structure may be used in conjunction with a sedimentation vessel in order to separate solids and liquids, which may be in a slurry, from each other. The feed structure comprises a feed chamber housing a central wall. At least one port is positioned at the base of the chamber. A feedwell that is substantially concentric with the feed chamber is also used. The feed chamber is in communication with the feedwell, wherein slurry flows through the said port to access the feedwell. An outlet is positioned on the feedwell (such as near the bottom of the feedwell). Slurry may flow through the outlet into the sedimentation vessel.

Abstract: A feed system is used in a sedimentation vessel. The feed system includes an inlet for receiving a quantity of feed slurry and an outlet for delivering the feed slurry to a separation zone within the sedimentation vessel. The feed slurry includes a mixture of solids and liquids that are to be separated in a separation zone within the sedimentation vessel. An airlift pump is used to cycle at least a portion of either the separated solids or the separated liquids from the separation zone and return it to the feed system. This returned portion mixes with the feed slurry and may operate to dilute the feed slurry to a concentration for optimal separation. Additionally, feed conditioning chemicals may be mixed into the feed slurry prior to or after the mixing of the feed slurry with the returned portion of the separated products.

Abstract: The present invention pertains to the use of a PKC inhibitor in the treatment of insulin-producing cell and tissue rejection, such as islet transplantation rejection or rejection of transdifferentiated insulin-producing hepatocytes.

Abstract: The invention provides a pharmaceutical combination comprising: a) at least one S1P receptor agonist, and b) at least one JAK3 kinase inhibitor and a method for treating or preventing autoimmune diseases or cell, tissue or organ graft rejection using such a combination.

Abstract: A pharmaceutical combination comprising an accelerated lymphocyte homing agent in free form or in pharmaceutically acceptable salt form, and one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor is used to treat or prevent insulin-producing cell graft rejection.

Abstract: The invention relates to anhydrous crystalline valaciclovir hydrochloride, pharmaceutical compositions containing the same, its use in medical therapy and processes for preparing the same.

Abstract: A pharmaceutical combination comprising an accelerated lymphocyte homing agent in free form or in pharmaceutically acceptable salt form, and one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor is used to treat or prevent insulin-producing cell graft rejection.

Abstract: A method for inducing or modulating T or B cells tolerance to donor cells, tissue or organ in a recipient comprising administering to the recipient a LFA-1 inhibitor in combination with a costimulation inhibitor and/or a mTOR inhibitor.